{
    "nctId": "NCT00334542",
    "briefTitle": "Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer",
    "officialTitle": "A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:\n\n  * Ductal carcinoma in situ\n  * Stage I-III invasive breast cancer\n* At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy\n\n  * May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed \u2265 3 months ago\n* At least 1 healthy intact breast\n\n  * No prior radiotherapy or mastectomy\n  * Prior biopsies allowed\n* Any hormone-receptor status\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Pre- or post-menopausal\n* ECOG performance status 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective nonhormonal contraception\n* No active liver disease\n* AST and ALT \u2264 3 times upper limit of normal\n* Creatinine clearance \u2265 30 mL/min\n* No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components\n* No other concurrent infectious, inflammatory, or autoimmune diseases (at the discretion of principal investigator)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No daily alcohol use \\> 3 standard drinks per day\n\n  * Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor\n* No selective estrogen receptor modulator or aromatase inhibitor within the past 3 months\n* No hormone replacement therapy (HRT) within the past 3 months\n* No prior estrogen and/or progesterone HRT \u2265 5 years in duration\n\n  * Vaginal estrogen preparations allowed\n* No concurrent HRT\n* No other cholesterol-lowering drug, including a statin, within the past 3 months\n* No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan, chaparral, amiodarone, or verapamil\n* No concurrent daily grapefruit juice consumption \\> 8 ounces per day\n* No other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}